dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: CLK family (type: enzyme)
Target: CDC like kinase 4

Ligand: compound 17 [PMID: 23642479] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
Published in: Bioorg Med Chem Lett

Ligand: compound 3b [PMID: 23454515] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.210000038146973 pIC50
Reference (Journal): Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Published in: Eur J Med Chem

Ligand: kinase inhibitor 2 [PMID: 30199702] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Journal): A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Published in: Eur J Med Chem

Ligand: ML315 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.170000076293945 pIC50
Reference (Journal): Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
Published in: Bioorg Med Chem Lett

Ligand: MW01 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): CLK2 and CLK4 are regulators of DNA damage-induced NF-&#x3ba;B targeted by novel small molecule inhibitors.
Published in: Cell Chem Biol

Ligand: MW05 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.510000228881836 pIC50
Reference (Journal): CLK2 and CLK4 are regulators of DNA damage-induced NF-&#x3ba;B targeted by novel small molecule inhibitors.
Published in: Cell Chem Biol

Ligand: tomivosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Published in: J Med Chem
Target family: Complement peptide receptors (type: gpcr)
Target: C5a<sub>2</sub> receptor

Ligand: C5a des-Arg (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
Published in: J Biol Chem

Ligand: C5a des-Arg (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): C5L2, a nonsignaling C5A binding protein.
Published in: Biochemistry

Ligand: C5a des-Arg (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.640000343322754 pEC50

Ligand: C5a hexapeptide analogue (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.74 pIC50
Reference (Journal): C5L2, a nonsignaling C5A binding protein.
Published in: Biochemistry

Ligand: C5apep (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pEC50
Reference (Journal): Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.
Published in: J Biol Chem

Ligand: CHIPS-(28-149) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response.
Published in: Mol Immunol

Ligand: Eu-DTPA-[Ser27, Nle70]hC5a (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Mutations of the GREAT gene cause cryptorchidism.
Published in: Hum Mol Genet

Ligand: P32 [PMID: 27108698] (Peptide)
Interaction type: Agonist
Action: Biased agonist
Ligand approved: no
Primary target: no
Median affinity: 3.6500000953674316 pKi
Reference (Journal): Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.
Published in: Immunol Cell Biol

Ligand: P59 [PMID: 27108698] (Peptide)
Interaction type: Agonist
Action: Biased agonist
Ligand approved: no
Primary target: no
Median affinity: 4.190000057220459 pKi
Reference (Journal): Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.
Published in: Immunol Cell Biol

Ligand: [125I]C5a (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -
Target family: Complement peptide receptors (type: gpcr)
Target: C3a receptor

Ligand: SB290157 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): The &quot;C3aR Antagonist&quot; SB290157 is a Partial C5aR2 Agonist.
Published in: Front Pharmacol

Ligand: SB290157 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pIC50
Reference (Journal): Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models.
Published in: J Immunol

Ligand: SQ007-5 (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.650000095367432 pEC50
Reference (Journal): De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.
Published in: J Med Chem

Ligand: [125I]C3a (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.4 pKd
Reference (Journal): Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function.
Published in: J Biol Chem

Ligand: TLQP-21 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.940000057220459 pIC50
Reference (Journal): Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells.
Published in: J Biol Chem

Ligand: WWGKKYRASKLGLAR (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.9 pEC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: WWGKKYRASKLGLAR (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.7 pIC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem

Ligand: YSFKPMPLaR (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.7 pEC50
Reference (Journal): Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Published in: J Med Chem
Target family: Complement peptide receptors (type: gpcr)
Target: C3a receptor

Ligand: oryzatensin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin.
Published in: Biochem Mol Biol Int
Target family: Complement peptide receptors (type: gpcr)
Target: C5a<sub>1</sub> receptor

Ligand: CHIPS (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor.
Published in: J Immunol
Target family: Complement peptide receptors (type: gpcr)
Target: C5a<sub>2</sub> receptor

Ligand: A8Δ71-73 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism.
Published in: J Biol Chem

Ligand: C5a (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.850000381469727 pEC50
Reference (Journal): The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
Published in: J Biol Chem

Ligand: C5a (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): C5L2, a nonsignaling C5A binding protein.
Published in: Biochemistry

Ligand: C5a (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
Published in: J Biol Chem
Target family: Complement system regulators (type: other_protein)
Target: clusterin

Ligand: sotevtamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.350000381469727 pKd
Reference (Patent): Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx50

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx59

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx62

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Px1

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Px2

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Px3

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx30

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx23

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx25

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx26

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx47

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx46

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx45

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx43

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx40.1

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx40

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx37

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx36

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx32

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx31.9

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx31.1

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx31

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx30.3

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx30.2

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx47

Ligand: octanol (Metabolite)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Connexins and Pannexins (type: other_ic)
Target: Cx50

Ligand: Ca2+ (Inorganic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -

Ligand: carbenoxolone (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Median affinity:  -
Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV 3C-like (main) protease

Ligand: compound 15g {PMID: 34242027] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.1899995803833 pIC50
Reference (Journal): Peptidomimetic &#x3b1;-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and <i>in Vitro</i> Biological Stability.
Published in: J Med Chem